Advances in incretin-based therapeutics for obesity

Nature Reviews Endocrinology, Published online: 07 December 2023; doi:10.1038/s41574-023-00938-wThe year 2023 brought reports of highly effective glucagon-like peptide 1 (GLP1) mono-agonists or combinations with amylin receptor agonists. Results for monomolecular co-agonists that added glucagon receptor and/or glucose-dependent insulinotropic polypeptide (GIP) receptor agonism to GLP1 receptor activation were also published in 2023. Interestingly, antagonistic GIP receptor antibodies conjugated with a GLP1 agonist were also shown to be effective.
Source: Nature Reviews Endocrinology - Category: Endocrinology Authors: Source Type: research